Journal of global antimicrobial resistance · 2026
Aztreonam-avibactam against carbapenem-resistant Enterobacterales: Susceptibility and genomic analysis in a Chinese teaching hospital.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Qiaomin, Zhang Guili, Huang Hanlian, Cao Xinyi, Fang Zhencheng, Ma Wen, Dai Xiaoyan, Chen Zhongbiao, Shen Hongwei, Li Peng
Аннотация
OBJECTIVE: To investigate aztreonam-avibactam (AZA) susceptibility and molecular features of carbapenem-resistant Enterobacterales (CRE) at a Shenzhen hospital.
METHODS: CRE isolates were collected from January 2018 to September 2025 and analysed by whole-genome sequencing, AZA disk diffusion, and clinical data review. Regional phylogenetic analysis from multiple hospitals in Guangdong Province was conducted.
RESULTS: Among 8655 Enterobacterales isolates, 152 (1.8%) were CRE, with prevalence increasing from 0.3% (2018) to 2.5% (2025). Isolates were predominantly carbapenem-resistant Klebsiella pneumoniae (CRKP, n = 79) and Escherichia coli (CREC, n = 43), mainly from the intensive care unit (37.5%) and elderly patients (≥60 y, 55.9%). Ceftazidime-avibactam was 45.4% resistant overall, 91.5% susceptible to blaKPC-CRE, and 100% resistant to blaNDM-CRE. All isolates were susceptible to AZA. CRKP was dominated by the ST11-KL64 clone (46.8%), while CREC was genetically diverse. The blaKPC-2 predominated in CRKP (58.2%) and blaNDM-5 prevailed in CREC (74.4%). Notably, 40 carbapenemase-negative CRE isolates accounted for 26.3% of all CRE isolates during the study period. Key resistance genes in CRKP included rmtB (58.2%), qnrS1 (72.2%), blaCTX-M-65 (48.1%), blaLAP-2 (57.0%), blaSHV-134 (38.0%), and fosA6 (93.7%); those in CREC were dfrA12 (41.9%), floR (58.1%), and mphB (88.4%). Regional phylogeny demonstrated that local CRKP clustered within the provincially dominant ST11-KL64 epidemic clade, while CREC were intermixed with strains across Guangdong Province, indicating widespread regional transmission and multiple independent introduction events.
CONCLUSIONS: The rise of CRE driven by ST11-KL64 and a growing proportion of non-carbapenemase producers necessitates strengthened infection control. The universal in vitro AZA susceptibility offers a promising therapy.
METHODS: CRE isolates were collected from January 2018 to September 2025 and analysed by whole-genome sequencing, AZA disk diffusion, and clinical data review. Regional phylogenetic analysis from multiple hospitals in Guangdong Province was conducted.
RESULTS: Among 8655 Enterobacterales isolates, 152 (1.8%) were CRE, with prevalence increasing from 0.3% (2018) to 2.5% (2025). Isolates were predominantly carbapenem-resistant Klebsiella pneumoniae (CRKP, n = 79) and Escherichia coli (CREC, n = 43), mainly from the intensive care unit (37.5%) and elderly patients (≥60 y, 55.9%). Ceftazidime-avibactam was 45.4% resistant overall, 91.5% susceptible to blaKPC-CRE, and 100% resistant to blaNDM-CRE. All isolates were susceptible to AZA. CRKP was dominated by the ST11-KL64 clone (46.8%), while CREC was genetically diverse. The blaKPC-2 predominated in CRKP (58.2%) and blaNDM-5 prevailed in CREC (74.4%). Notably, 40 carbapenemase-negative CRE isolates accounted for 26.3% of all CRE isolates during the study period. Key resistance genes in CRKP included rmtB (58.2%), qnrS1 (72.2%), blaCTX-M-65 (48.1%), blaLAP-2 (57.0%), blaSHV-134 (38.0%), and fosA6 (93.7%); those in CREC were dfrA12 (41.9%), floR (58.1%), and mphB (88.4%). Regional phylogeny demonstrated that local CRKP clustered within the provincially dominant ST11-KL64 epidemic clade, while CREC were intermixed with strains across Guangdong Province, indicating widespread regional transmission and multiple independent introduction events.
CONCLUSIONS: The rise of CRE driven by ST11-KL64 and a growing proportion of non-carbapenemase producers necessitates strengthened infection control. The universal in vitro AZA susceptibility offers a promising therapy.
Предметные рубрики MeSH
HumansAzabicyclo CompoundsChinaMicrobial Sensitivity TestsAztreonamCarbapenem-Resistant EnterobacteriaceaeAnti-Bacterial AgentsHospitals, TeachingWhole Genome SequencingEnterobacteriaceae InfectionsPhylogenyKlebsiella pneumoniaeDrug CombinationsDrug Resistance, Multiple, BacterialCeftazidimeEscherichia coliGenome, BacterialCarbapenemsbeta-Lactamases